Park Square has placed Peter Renehan, M.D. as Vice President, Investments and Business Development at Ligand Pharmaceuticals, a leading royalty aggregator, which owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry.

Renehan most recently spent nearly six years at Blackstone, where he was a Principal in the Life Sciences investment group. Prior, he served as Healthcare Investment Banking Associate at Lazard. Earlier in his career, Renehan held internships with Flagship Pioneering and Moderna Therapeutics.

Renehan received his M.D. from Harvard Medical School, M.B.A. from Harvard Business School, and B.A. in Chemistry from College of the Holy Cross.